Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMeenakshi DevidasGCGunnar CarioGEGabriele Escherich

Discussion

Loading...

Member takes

Overview

Multinational cohort study shows impact of ABL-class fusions on EFS and OS in children with T-ALL, indicating treatment avenues.

Key Points

  • This study aims to detail the clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions.
  • Multinational retrospective cohort study
  • Data from 14 groups within the Ponte di Legno consortium
  • Patients included had newly-diagnosed T-ALL with ABL-class fusions
  • Clinical characteristics, treatments, and outcomes were analyzed
  • 196 pediatric patients with ABL-class T-ALL analyzed
  • 89.2% achieved morphologic complete remission
  • 5-year event-free survival was 78.1% and overall survival was 83.6%
  • Only HSCT in CR1 was associated with inferior EFS for non-BCR::ABL1 ABL-class T-ALL

Cite This Study

Devidas et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d034https://doi.org/10.1182/blood-2025-761
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcome of children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia: Results of DFCI ALL consortium protocol 16-0012025
  2. 2Abstract B039: Investigations on ethnographic disparities in molecular epidemiology of pediatric ALL and its impact on clinical outcome as well as cancer management planning strategies2024
  3. 3Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)2025
  4. 4Results of second‐line therapy in adult Philadelphia chromosome‐positive acute lymphoblastic leukemia2026
  5. 5Impact of P190 and P210 BCR-ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia in the Current Era2026